AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06147557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
Study NCT04527198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brainstem Responses Assessment Sedation Score (BRASS)
Description: It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning.
Study NCT04527198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalogram with EKG lead
Description: A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity).
Study NCT03135847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactor
Description: The tactor is a small robot providing touch and vibration.
Study NCT02847754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band
Study NCT01980472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab, carboplatin and paclitaxel
Description: 4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
Study NCT01385020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil & red yeast rice (LipoCol)
Description: The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
Study NCT00521521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Study NCT00521521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00122135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Values Inventory (VI)
Description: The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
Study NCT02396732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily dose is 81 mg oral tablet
Study NCT02396732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
Study NCT02396732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
Study NCT01894204 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HTPPE
Description: No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
Study NCT03484468 — intervention group
Intervention type: DEVICE
Intervention: anterior segment Ocular Coherence Tomography
Description: anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
Study NCT02264587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Description: Mosapride 5mg by mouth ,3 times one day for 1 4days.
Study NCT02264587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: Domperidone 10mg by mouth ,3 times one day for 1 4days.
Study NCT00697671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NK Cell Infusion
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
Study NCT02778113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Administered SC.
Study NCT04500561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
Study NCT00697671 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Immunotherapy
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT00697671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS device
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT00697671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Interleukin-2 (IL-2)
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT00697671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT00697671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT00697671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
Study NCT03370159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV
Study NCT03370159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03370159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03472560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: IV treatment: Avelumab administered at 800 mg IV every two weeks
Study NCT03472560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Oral treatment: Axitinib given 5 mg PO BID
Study NCT00485888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipralex
Description: 10-20mg; one per day
Study NCT00485888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to Cipralex
Study NCT01534676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.
Study NCT01534676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.
Study NCT01534676 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)
Study NCT01534676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)
Study NCT01534676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chelation therapy
Description: (non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
Study NCT01534676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Description: (non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
Study NCT00305656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT01533675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
Study NCT01533675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Once daily topical application of normal saline, using a cotton-tipped applicator
Study NCT04204174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tyrosine, brand name: myprotein
Description: tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
Study NCT03542396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPuls
Description: Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
Study NCT01764919 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: A single intravenous injection of 5 mCi\[124I\]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
Study NCT00294619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: subcutaneous injection, once-weekly
Study NCT00294619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: growth hormone
Description: subcutaneous injection, once-weekly
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 iv, day 1 every third week, 4 courses preoperatively.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 iv, day 1 every third week, 4 courses preoperatively.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
Study NCT03894007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.
Study NCT00922727 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.
Study NCT00922727 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Study NCT04408560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)
Description: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH
Study NCT04408560 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol (drug analgesic class1)
Description: paracetamol (drug analgesic class1)
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Study NCT04408560 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: paracetamol (drug analgesic class1)
Description: paracetamol (drug analgesic class1)
Study NCT02925949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DuoPACT
Description: 6 couple-based intervention sessions are administered weekly by a counselor.
Study NCT02925949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LifeSteps
Description: 3 individual-based intervention sessions are administered weekly by a counselor.
Study NCT04152564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine infusion via Thoracic epidural catheter
Description: The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
Study NCT04152564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine infusion via preperitoneal catheter
Description: At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
Study NCT00271505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: 15 mg/kg intravenously (IV) every 3 weeks
Study NCT00271505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 IV every 3 weeks
Study NCT00271505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV every 3 weeks
Study NCT04189185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture fixation
Description: The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
Study NCT01537614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIMYCINE inhalation
Description: 2 MILLION UI
Study NCT01537614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIMYCINE injectable
Description: 2 MILLIONS UI
Study NCT02345564 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: implantation of MaioRegen fleece into osteochondral lesion
Description: arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
Study NCT04849702 — intervention group
Intervention type: PROCEDURE
Intervention: No intervention was compared
Description: No intervention was compared
Study NCT01893034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic treatment of femoroacetabular impingement
Study NCT01893034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and activity modification
Study NCT01777152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
Study NCT00625664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: administered on day 1 as a 1-hour infusion
Study NCT00625664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: administered on day 1, 8 and 15 as a 30-minute infusion